Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Recent Articles

CASI Signs $10 Million Out-licensing of CD38 for Autoimmune Indications to Tianshi
CanSino One-Shot COVID Vaccine Accepted by WHO
Fosun Acquires Novel Cancer Immunotherapy in $125 Million Deal
CTTQ Acquires Global Rights to Clinical Stage Symphogen Immunotherapy
Week in Review: Hengrui Launches US Subsidiary to Bring Novel Medicines to Global Markets
ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022